Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative-Reference-Cited by-同舟云学术

Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative

Published:2023-10 Issue:10 Volume:16 Page:
ISSN:1941-7713
Container-title:Circulation: Cardiovascular Quality and Outcomes
language:en
Short-container-title:Circ: Cardiovascular Quality and Outcomes

Author:

Teske Arco J.¹^ORCID,Moudgil Rohit²^ORCID,López-Fernández Teresa³^ORCID,Barac Ana⁴^ORCID,Brown Sherry Ann⁵,Deswal Anita⁶^ORCID,Neilan Tomas G.⁷^ORCID,Ganatra Sarju⁸,Abdel Qadir Husam⁹,Menon Venu²^ORCID,Sverdlov Aaron L.¹⁰^ORCID,Cheng Richard K.¹¹^ORCID,Makhoul Silvia¹²^ORCID,Ghosh Arjun K.¹³¹⁴¹⁵^ORCID,Szmit Sebastian¹⁶^ORCID,Zaha Vlad¹⁷^ORCID,Addison Daniel¹⁸^ORCID,Zhang Lili¹⁹,Herrmann Joerg²⁰,Chong Jun H.²¹,Agarwala Vivek²²^ORCID,Iakobishvili Zaza²³^ORCID,Guerrero Patricia²⁴,Yang Eric H.²⁵^ORCID,Leja Monika²⁶,Akhter Nausheen²⁷^ORCID,Guha Avirup²⁸^ORCID,Okwuosa Tochukwu M.²⁹^ORCID,Silva Carolina Carvalho³⁰,Collier Patrick²^ORCID,DeCara Jeanne³¹^ORCID,Bauer Brenton³²^ORCID,Lenneman Carrie E.³³,Sadler Diego³⁴^ORCID

Affiliation:

1. Department of Cardiology, University Medical Centre Utrecht, The Netherlands (A.J.T.).

2. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, OH (R.M., V.M., P.C.).

3. Hospital Universitario La Paz, Madrid, Spain (T.L.-F.).

4. Medstar Heart Institute, Georgetown University, WA, DC (A.B.).

5. Medical College of Wisconsin, Milwaukee (S.A.B.).

6. MD Anderson Cancer Center, Houston, TX (A.D.).

7. Massachusetts General Hospital, Harvard Medical School, Boston (T.G.N.).

8. Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA (S.G.).

9. University of Toronto, Canada (H.A.Q.).

10. Newcastle Centre of Excellence in Cardio-Oncology, Calvary Mater Newcastle, Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, NSW, Australia (A.L.S.).

11. University of Washington Medical Center, Seattle (R.K.C.).

12. Hospital Juan A Fernández/Hospital Británico de Buenos Aires Buenos Aires, Argentina (S.M.).

13. Barts Heart Centre, St Bartholomew’s Hospital (A.K.G.), London, United Kingdom.

14. University College London Hospital (A.K.G.), London, United Kingdom.

15. Hatter Cardiovascular Institute (A.K.G.), London, United Kingdom.

16. Centre of Postgraduate Medical Education, Warsaw, Poland (S.S.).

17. UT Southwestern Medical Center, Dallas, TX (V.Z.).

18. Ohio State University, Columbus (D.A.).

19. Montefiore Medical Center/Albert Einstein College of Medicine, NY (L.Z.).

20. Mayo Clinic, Rochester, MN (J.H.).

21. National Heart Centre, Singapore (J.H.C.).

22. Narayana Superspeciality Hospital and Cancer Institute and RN Tagore Cancer Center, Kolkata, India (V.A.).

23. Department of Cardiology, Tel Aviv Jaffa District Clalit Health Services, Tel Aviv, Israel (Z.I.).

24. AdventHealth, Orlando, FL (P.G.).

25. University of California Los Angeles (E.H.Y.).

26. University of Michigan Medical Center, Ann Arbor (M.L.).

27. Northwestern University Feinberg School of Medicine, Chicago, IL (N.A.).

28. Cardio-Oncology Program, Department of Medicine, Georgia Cancer Center, Medical College of Georgia at Augusta University, GA (A.G.).

29. Rush University Medical Center, Chicago, IL (T.M.O.).

30. Rede D’Or Hospital Group, Sao Paulo, Brazil (C.C.S.).

31. University of Chicago School of Medicine, IL (J.D.C.).

32. COR Healthcare Associates/Torrance Memorial Medical Center, CA (B.B.).

33. University of Alabama at Birmingham (C.E.L.).

34. Cleveland Clinic Florida, Weston (D.S.).

Abstract

BACKGROUND: Global collaboration in cardio-oncology is needed to understand the prevalence of cancer therapy-related cardiovascular toxicity in different risk groups, practice settings, and geographic locations. There are limited data on the socioeconomic and racial/ethnic disparities that may impact access to care and outcomes. To address these gaps, we established the Global Cardio-Oncology Registry, a multinational, multicenter prospective registry. METHODS: We assembled cardiologists and oncologists from academic and community settings to collaborate in the first Global Cardio-Oncology Registry. Subsequently, a survey for site resources, demographics, and intention to participate was conducted. We designed an online data platform to facilitate this global initiative. RESULTS: A total of 119 sites responded to an online questionnaire on their practices and main goals of the registry: 49 US sites from 23 states and 70 international sites from 5 continents indicated a willingness to participate in the Global Cardio-Oncology Registry. Sites were more commonly led by cardiologists (85/119; 72%) and were more often university/teaching (81/119; 68%) than community based (38/119; 32%). The average number of cardio-oncology patients treated per month was 80 per site. The top 3 Global Cardio-Oncology Registry priorities in cardio-oncology care were breast cancer, hematologic malignancies, and patients treated with immune checkpoint inhibitors. Executive and scientific committees and specific committees were established. A pilot phase for breast cancer using Research Electronic Data Capture Cloud platform recently started patient enrollment. CONCLUSIONS: We present the structure for a global collaboration. Information derived from the Global Cardio-Oncology Registry will help understand the risk factors impacting cancer therapy-related cardiovascular toxicity in different geographic locations and therefore contribute to reduce access gaps in cardio-oncology care. Risk calculators will be prospectively derived and validated.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference40 articles.

1. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines

2. The year in cardiovascular medicine 2021: cardio-oncology.;Herrmann J;Eur Heart J,2022

3. JACC: CardioOncology: Poised to Serve a Maturing, Collaborative Field

4. Cardio-Oncology Services: rationale, organization, and implementation

5. Cardio-oncology: an overview on outpatient management and future developments

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular risk in cancer patients treated with immune checkpoint inhibitors: challenges and future directions;European Journal of Preventive Cardiology;2024-06-13

2. Core outcome set for cardio-oncology: development of a set of outcomes for the cardiovascular assessment and monitoring of cancer patients and survivors;European Heart Journal - Quality of Care and Clinical Outcomes;2024-05-25

3. Prevention and treatment of anthracycline-induced cardiotoxicity: A bibliometric analysis of the years 2000–2023;Heliyon;2024-05

4. Integrating Cardio-Oncology Across the Research Pipeline, Policy, and Practice in Australia—An Australian Cardiovascular Alliance Perspective;Heart, Lung and Circulation;2024-05

5. Program Building in Cardio-oncology: Bridging Existing Care Gaps to Improve Cardiovascular and Cancer Outcomes;Current Treatment Options in Cardiovascular Medicine;2024-01-23